Type 2 Diabetes - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 1298 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2016, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 18, 25, 71, 54, 6, 252, 85 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 66 and 20 molecules, respectively.Type 2 Diabetes.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2

Introduction 12
Type 2 Diabetes Overview 13
Therapeutics Development 14
Type 2 Diabetes - Therapeutics under Development by Companies 16
Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 36
Type 2 Diabetes - Pipeline Products Glance 40
Type 2 Diabetes - Products under Development by Companies 44
Type 2 Diabetes - Products under Investigation by Universities/Institutes 78
Type 2 Diabetes - Companies Involved in Therapeutics Development 84
Type 2 Diabetes - Therapeutics Assessment 313
Drug Profiles 368
Type 2 Diabetes - Dormant Projects 1156
Type 2 Diabetes - Discontinued Products 1204
Type 2 Diabetes - Product Development Milestones 1223

Appendix 1236

List of Tables

Number of Products under Development for Type 2 Diabetes, H2 2016 75
Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2016 76
Number of Products under Development by Companies, H2 2016 78
Number of Products under Development by Companies, H2 2016 (Contd..1) 79
Number of Products under Development by Companies, H2 2016 (Contd..2) 80
Number of Products under Development by Companies, H2 2016 (Contd..3) 81
Number of Products under Development by Companies, H2 2016 (Contd..4) 82
Number of Products under Development by Companies, H2 2016 (Contd..5) 83
Number of Products under Development by Companies, H2 2016 (Contd..6) 84
Number of Products under Development by Companies, H2 2016 (Contd..7) 85
Number of Products under Development by Companies, H2 2016 (Contd..8) 86
Number of Products under Development by Companies, H2 2016 (Contd..9) 87
Number of Products under Development by Companies, H2 2016 (Contd..10) 88
Number of Products under Development by Companies, H2 2016 (Contd..11) 89
Number of Products under Development by Companies, H2 2016 (Contd..12) 90
Number of Products under Development by Companies, H2 2016 (Contd..13) 91
Number of Products under Development by Companies, H2 2016 (Contd..14) 92
Number of Products under Development by Companies, H2 2016 (Contd..15) 93
Number of Products under Development by Companies, H2 2016 (Contd..16) 94
Number of Products under Development by Companies, H2 2016 (Contd..17) 95
Number of Products under Development by Companies, H2 2016 (Contd..18) 96
Number of Products under Investigation by Universities/Institutes, H2 2016 97
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 98
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 99
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 100
Comparative Analysis by Late Stage Development, H2 2016 101
Comparative Analysis by Clinical Stage Development, H2 2016 102
Comparative Analysis by Early Stage Development, H2 2016 103
Comparative Analysis by Unknown Stage Development, H2 2016 104
Products under Development by Companies, H2 2016 105
Products under Development by Companies, H2 2016 (Contd..1) 106
Products under Development by Companies, H2 2016 (Contd..2) 107
Products under Development by Companies, H2 2016 (Contd..3) 108
Products under Development by Companies, H2 2016 (Contd..4) 109
Products under Development by Companies, H2 2016 (Contd..5) 110
Products under Development by Companies, H2 2016 (Contd..6) 111
Products under Development by Companies, H2 2016 (Contd..7) 112
Products under Development by Companies, H2 2016 (Contd..8) 113
Products under Development by Companies, H2 2016 (Contd..9) 114
Products under Development by Companies, H2 2016 (Contd..10) 115
Products under Development by Companies, H2 2016 (Contd..11) 116
Products under Development by Companies, H2 2016 (Contd..12) 117
Products under Development by Companies, H2 2016 (Contd..13) 118
Products under Development by Companies, H2 2016 (Contd..14) 119
Products under Development by Companies, H2 2016 (Contd..15) 120
Products under Development by Companies, H2 2016 (Contd..16) 121
Products under Development by Companies, H2 2016 (Contd..17) 122
Products under Development by Companies, H2 2016 (Contd..18) 123
Products under Development by Companies, H2 2016 (Contd..19) 124
Products under Development by Companies, H2 2016 (Contd..20) 125
Products under Development by Companies, H2 2016 (Contd..21) 126
Products under Development by Companies, H2 2016 (Contd..22) 127
Products under Development by Companies, H2 2016 (Contd..23) 128
Products under Development by Companies, H2 2016 (Contd..24) 129
Products under Development by Companies, H2 2016 (Contd..25) 130
Products under Development by Companies, H2 2016 (Contd..26) 131
Products under Development by Companies, H2 2016 (Contd..27) 132
Products under Development by Companies, H2 2016 (Contd..28) 133
Products under Development by Companies, H2 2016 (Contd..29) 134
Products under Development by Companies, H2 2016 (Contd..30) 135
Products under Development by Companies, H2 2016 (Contd..31) 136
Products under Development by Companies, H2 2016 (Contd..32) 137
Products under Development by Companies, H2 2016 (Contd..33) 138
Products under Investigation by Universities/Institutes, H2 2016 139
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 140
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 141
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 142
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 143
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 144
Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H2 2016 145
Type 2 Diabetes - Pipeline by Adocia, H2 2016 146
Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H2 2016 147
Type 2 Diabetes - Pipeline by Aegis Therapeutics, LLC, H2 2016 148
Type 2 Diabetes - Pipeline by AFFiRiS AG, H2 2016 149
Type 2 Diabetes - Pipeline by Alize Pharma SAS, H2 2016 150
Type 2 Diabetes - Pipeline by AlphaMab Co., Ltd, H2 2016 151
Type 2 Diabetes - Pipeline by Alteogen Inc., H2 2016 152
Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 153
Type 2 Diabetes - Pipeline by Ambrx, Inc., H2 2016 154
Type 2 Diabetes - Pipeline by Amgen Inc., H2 2016 155
Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H2 2016 156
Type 2 Diabetes - Pipeline by AntriaBio, Inc., H2 2016 157
Type 2 Diabetes - Pipeline by Aphios Corporation, H2 2016 158
Type 2 Diabetes - Pipeline by APT Therapeutics, Inc., H2 2016 159
Type 2 Diabetes - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 160
Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 161
Type 2 Diabetes - Pipeline by ArisGen SA, H2 2016 162
Type 2 Diabetes - Pipeline by Artery Therapeutics, Inc., H2 2016 163
Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H2 2016 164
Type 2 Diabetes - Pipeline by AstraZeneca Plc, H2 2016 165
Type 2 Diabetes - Pipeline by Aus Bio Ltd, H2 2016 166
Type 2 Diabetes - Pipeline by Bayer AG, H2 2016 167
Type 2 Diabetes - Pipeline by Beta-Cell NV, H2 2016 168
Type 2 Diabetes - Pipeline by Betagenon AB, H2 2016 169
Type 2 Diabetes - Pipeline by Biocon Limited, H2 2016 170
Type 2 Diabetes - Pipeline by Biodel Inc., H2 2016 171
Type 2 Diabetes - Pipeline by Biogenomics Limited, H2 2016 172
Type 2 Diabetes - Pipeline by BioLingus AG, H2 2016 173
Type 2 Diabetes - Pipeline by BioRestorative Therapies, Inc., H2 2016 174
Type 2 Diabetes - Pipeline by BioTherapeutics Inc., H2 2016 175
Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 176
Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H2 2016 177
Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H2 2016 178
Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H2 2016 179
Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H2 2016 180
Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H2 2016 181
Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Limited, H2 2016 182
Type 2 Diabetes - Pipeline by Caldan Therapeutics Limited, H2 2016 183
Type 2 Diabetes - Pipeline by Cardax, Inc., H2 2016 184
Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H2 2016 185
Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H2 2016 186
Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H2 2016 187
Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H2 2016 188
Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 189
Type 2 Diabetes - Pipeline by CJ HealthCare Corp., H2 2016 190
Type 2 Diabetes - Pipeline by CohBar, Inc., H2 2016 191
Type 2 Diabetes - Pipeline by ConjuChem, LLC, H2 2016 192
Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 193
Type 2 Diabetes - Pipeline by Corium International, Inc., H2 2016 194
Type 2 Diabetes - Pipeline by CureDM, Inc., H2 2016 195
Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H2 2016 196
Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 197
Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 198
Type 2 Diabetes - Pipeline by Dance Biopharm Inc., H2 2016 199
Type 2 Diabetes - Pipeline by Delpor, Inc., H2 2016 200
Type 2 Diabetes - Pipeline by Diabetica Limited, H2 2016 201
Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H2 2016 202
Type 2 Diabetes - Pipeline by DiaMedica Inc., H2 2016 203
Type 2 Diabetes - Pipeline by Diamyd Medical AB, H2 2016 204
Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals, Inc., H2 2016 205
Type 2 Diabetes - Pipeline by DiscoveryBiomed, Inc., H2 2016 206
Type 2 Diabetes - Pipeline by DNJ Pharma, Inc., H2 2016 207
Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 208
Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H2 2016 209
Type 2 Diabetes - Pipeline by Eli Lilly and Company, H2 2016 210
Type 2 Diabetes - Pipeline by enGene, Inc, H2 2016 211
Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H2 2016 212
Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H2 2016 213
Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H2 2016 214
Type 2 Diabetes - Pipeline by Eternygen GmbH, H2 2016 215
Type 2 Diabetes - Pipeline by Evotec AG, H2 2016 216
Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 217
Type 2 Diabetes - Pipeline by FibroStatin SL, H2 2016 218
Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H2 2016 219
Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H2 2016 220
Type 2 Diabetes - Pipeline by Genfit SA, H2 2016 221
Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H2 2016 222
Type 2 Diabetes - Pipeline by Gero Corp, H2 2016 223
Type 2 Diabetes - Pipeline by Geropharm, H2 2016 224
Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H2 2016 225
Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H2 2016 226
Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 227
Type 2 Diabetes - Pipeline by Glucox Biotech AB, H2 2016 228
Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H2 2016 229
Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 230
Type 2 Diabetes - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 231
Type 2 Diabetes - Pipeline by Handok Inc., H2 2016 232
Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 233
Type 2 Diabetes - Pipeline by HEC Pharm Co., Ltd., H2 2016 234
Type 2 Diabetes - Pipeline by Heptares Therapeutics Limited, H2 2016 235
Type 2 Diabetes - Pipeline by HitGen LTD, H2 2016 236
Type 2 Diabetes - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 237
Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 238
Type 2 Diabetes - Pipeline by Immuron Limited, H2 2016 239
Type 2 Diabetes - Pipeline by Innopharmax Inc., H2 2016 240
Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H2 2016 241
Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H2 2016 242
Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 243
Type 2 Diabetes - Pipeline by Integral Molecular, Inc., H2 2016 244
Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 245
Type 2 Diabetes - Pipeline by Intrexon Corporation, H2 2016 246
Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 247
Type 2 Diabetes - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 248
Type 2 Diabetes - Pipeline by Islet Sciences, Inc., H2 2016 249
Type 2 Diabetes - Pipeline by Ixchel Pharma, LLC, H2 2016 250
Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H2 2016 251
Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 252
Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H2 2016 253
Type 2 Diabetes - Pipeline by JHL Biotech, Inc., H2 2016 254
Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016 255
Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 256
Type 2 Diabetes - Pipeline by Johnson & Johnson, H2 2016 257
Type 2 Diabetes - Pipeline by Kadimastem Ltd., H2 2016 258
Type 2 Diabetes - Pipeline by Kadmon Corporation, LLC, H2 2016 259
Type 2 Diabetes - Pipeline by Kareus Therapeutics, SA, H2 2016 260
Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 261
Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H2 2016 262
Type 2 Diabetes - Pipeline by Leading BioSciences, Inc., H2 2016 263
Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 264
Type 2 Diabetes - Pipeline by LG Life Science LTD., H2 2016 265
Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 266
Type 2 Diabetes - Pipeline by LipimetiX Development Inc, H2 2016 267
Type 2 Diabetes - Pipeline by Lonestar Heart, Inc., H2 2016 268
Type 2 Diabetes - Pipeline by Longevity Biotech, Inc, H2 2016 269
Type 2 Diabetes - Pipeline by Magnus Life Ltd, H2 2016 270
Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H2 2016 271
Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H2 2016 272
Type 2 Diabetes - Pipeline by MedImmune LLC, H2 2016 273
Type 2 Diabetes - Pipeline by Mellitech SAS, H2 2016 274
Type 2 Diabetes - Pipeline by Merck & Co., Inc., H2 2016 275
Type 2 Diabetes - Pipeline by Mesoblast Limited, H2 2016 276
Type 2 Diabetes - Pipeline by Metabolic Solutions Development Company, LLC, H2 2016 277
Type 2 Diabetes - Pipeline by Metabolys SAS, H2 2016 278
Type 2 Diabetes - Pipeline by Metacrine, Inc., H2 2016 279
Type 2 Diabetes - Pipeline by MicroBiome Therapeutics LLC, H2 2016 280
Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H2 2016 281
Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 282
Type 2 Diabetes - Pipeline by Moderna Therapeutics Inc, H2 2016 283
Type 2 Diabetes - Pipeline by Naia Limited, H2 2016 284
Type 2 Diabetes - Pipeline by Neurimmune Holding AG, H2 2016 285
Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H2 2016 286
Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 287
Type 2 Diabetes - Pipeline by Nordic Bioscience A/S, H2 2016 288
Type 2 Diabetes - Pipeline by Novapeutics, LLC, H2 2016 289
Type 2 Diabetes - Pipeline by Novartis AG, H2 2016 290
Type 2 Diabetes - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 291
Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H2 2016 292
Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H2 2016 293
Type 2 Diabetes - Pipeline by Ogeda SA, H2 2016 294
Type 2 Diabetes - Pipeline by Omeros Corporation, H2 2016 295
Type 2 Diabetes - Pipeline by OPKO Biologics Ltd, H2 2016 296
Type 2 Diabetes - Pipeline by OPKO Health, Inc., H2 2016 297
Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H2 2016 298
Type 2 Diabetes - Pipeline by Orbis Biosciences Inc, H2 2016 299
Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H2 2016 300
Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 301
Type 2 Diabetes - Pipeline by Peptron, Inc., H2 2016 302
Type 2 Diabetes - Pipeline by Pfizer Inc., H2 2016 303
Type 2 Diabetes - Pipeline by PharmaCyte Biotech, Inc., H2 2016 304
Type 2 Diabetes - Pipeline by PharmaIN Corporation, H2 2016 305
Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 306
Type 2 Diabetes - Pipeline by Pila Pharma AB, H2 2016 307
Type 2 Diabetes - Pipeline by Pivot Pharmaceuticals Inc, H2 2016 308
Type 2 Diabetes - Pipeline by Poxel SA, H2 2016 309
Type 2 Diabetes - Pipeline by Prometheon Pharma, LLC, H2 2016 310
Type 2 Diabetes - Pipeline by ProMetic Life Sciences Inc., H2 2016 311
Type 2 Diabetes - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016 312
Type 2 Diabetes - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 313
Type 2 Diabetes - Pipeline by ReCyte Therapeutics, Inc., H2 2016 314
Type 2 Diabetes - Pipeline by Red Glead Discovery AB, H2 2016 315
Type 2 Diabetes - Pipeline by RegenMedTX, LLC, H2 2016 316
Type 2 Diabetes - Pipeline by reMYND NV, H2 2016 317
Type 2 Diabetes - Pipeline by Renova Therapeutics Inc, H2 2016 318
Type 2 Diabetes - Pipeline by Saniona AB, H2 2016 319
Type 2 Diabetes - Pipeline by Sanofi, H2 2016 320
Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 321
Type 2 Diabetes - Pipeline by SATT Conectus Alsace SAS, H2 2016 322
Type 2 Diabetes - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 323
Type 2 Diabetes - Pipeline by Selvita S.A., H2 2016 324